Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.55 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315201 | 0.90 | SLC6A4 (0.61) | TACR1SLC6A4SLC6A2SLC6A3DCUN1D1 | |
| SCHEMBL4309337 | 0.86 | TACR1 (0.62) | TACR1SLC6A4SLC6A2SLC6A3HTR2C | |
| SCHEMBL4306745 | 0.86 | TACR1 (0.62) | TACR1SLC6A4SLC6A2SLC6A3HTR2C | |
| SCHEMBL4305445 | 0.84 | SLC6A2 (0.60) | TACR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4309725 | 0.84 | SLC6A2 (0.56) | TACR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4309655 | 0.82 | SLC6A4 (0.68) | TACR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4304090 | 0.81 | SLC6A2 (0.60) | TACR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4311495 | 0.79 | DCUN1D1 (0.48) | TACR1DCUN1D1 | |
| SCHEMBL4307130 | 0.79 | SLC6A2 (0.58) | TACR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL27614645 | 0.78 | SLC6A4 (0.62) | TACR1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488741-B2 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB PHARMA, S.A. (BE) | 2009-02-10 | — | — | US | disclosed |
| EP-1693061-A1 | Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases | UCB, S.A. (BE) | 2006-08-23 | — | — | EP | disclosed |
| EP-1556045-B1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB SA (BE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB, S.A. (BE) | 2006-06-15 | — | — | US | disclosed |
| EP-1556045-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004030668-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | PNMT, HTR5A, HTR4 | TACR1 1720/4885SLC6A4 50/4885SLC6A2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.